Background: Owing to the cost of HBV viral loads, in most resource-limited settings (RLS) only HBsAg testing is done. This leads to under diagnosis of HBV infection by ignoring occult HBV infection (OHI). Thus, we studied the prevalence of HBV and OHI among HIV infected individuals and evaluated a pooling HBV nucleic acid test (NAT) as a cost-effective alternative to conventional HBV viral load testMethods: ART-naïve, 502 HIV-1 infected individuals visiting YRG CARE were enrolled; median age was 36 years (IQR 31-40) and CD4 count was 381.5 cells/µL (IQR 232.5-540.25). HBV infection was detected by HBsAg ELISA (Genedia, Korea) followed by anti-HBc, anti-HBs ELISA (DiaSorin, Italy) and HBV DNA PCR was performed among all HBsAg negative individuals to find OHI. Pooling HBV NAT was performed in a matrix of 5×5 pooled samples, i.e. 25 plasma samples, and was evaluated against the gold standard HBV viral load (Abbott HBV RealTime PCR, linearity 1 – 9 log IU/mL) for cost and accuracyResults: The prevalence of HIV/HBV co-infection by HBsAg positivity was 6% (32/502, 95% CI 4.5%-8.86%). To test for OHI, we randomly selected 270 HBsAg negative individuals and performed HBV viral loads, anti-HBc and anti-HBs ELISA and found an overall prevalence of OHI as 10% (27/270, 95% CI 6.81%-1.44%) based on HBV DNA positivity, of which 96.3% (26/27) and 25.9% (7/27) were positive for anti-HBc and anti-HBs, respectively. This shows OHI is associated with anti-HBc alone (OR 9.46, p 0.1846) compared to anti-HBs. Compared to individual HBV viral loads, pooling HBV NAT had a positive predictive value of 100% and negative predictive value of 96.43%, with 100% specificity and 66.67% sensitivity. There would also have been cost (37$ vs. 91$) saving with pooling HBV NATConclusions: The prevalence of OHI is high among HIV-infected individuals in India, which would be missed by routine serology tests, thus HBV DNA testing should also be considered. However, conventional HBV viral loads are expensive in RLS, thus pooling HBV NAT should be considered, as it could reduce assay costs by up to 40%